Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
We couldn't find that product
But the reality is far more nuanced, touching on everything from gastrointestinal physiology to the molecular stability of the peptide itself
Sold strictly for in-vitro and laboratory research purposes
PL BioScience has advanced an oral BPC-157 formulation (designated PL-10) to Phase II clinical trials for inflammatory bowel disease representing the most clinically advanced human development of oral BPC-157 to date.3 Human peer-reviewed results from these trials are pending, but the preclinical rationale is strong
These trials should follow standardized dosing, objective endpoints, and rigorous safety protocols
If BPC-157 acts via VEGFR2, blocking it should abolish the effect
